Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Feb;23(2):120-127.
doi: 10.1089/dia.2020.0388. Epub 2020 Sep 10.

Real-World Patient-Reported Outcomes and Glycemic Results with Initiation of Control-IQ Technology

Jordan E Pinsker  1 , Lars Müller  2 , Alexandra Constantin  3 , Scott Leas  3 , Michelle Manning  4 , Molly McElwee Malloy  4 , Harsimran Singh  4 , Steph Habif  4
Affiliations

Real-World Patient-Reported Outcomes and Glycemic Results with Initiation of Control-IQ Technology

Jordan E Pinsker et al. Diabetes Technol Ther. 2021 Feb.

Abstract

Background: The t:slim X2™ insulin pump with Control-IQ™ technology, an advanced hybrid closed-loop system, became available in the United States in early 2020. Real-world outcomes with use of this system have not yet been comprehensively reported. Methods: Individuals with type 1 diabetes (T1D) (≥14 years of age) who had ≥21 days of pump usage data were invited via email to participate. Participants completed psychosocial questionnaires (Technology Acceptance Scale [TAS], well-being index [WHO-5], and Diabetes Impact and Devices Satisfaction [DIDS] scale) at timepoint 1 (T1) (at least 3 weeks after starting Control-IQ technology) and the DIDS and WHO-5 at timepoint 2 (T2) (4 weeks from T1). Patient-reported outcomes (PROs) and glycemic outcomes were reviewed at each timepoint. Results: Overall, 9,085 potentially eligible individuals received the study invite. Of these, 3,116 consented and subsequently 1,435 participants completed questionnaires at both T1 and T2 and had corresponding glycemic data available on the t:connect® web application. Time in range was 78.2% (70.2%-85.1%) at T1 and 79.2% (70.3%-86.2%) at T2. PROs reflected high device-related satisfaction and reduced diabetes impact at T2. Factors contributing to high trust in the system included sensor accuracy, improved diabetes control, reduction in extreme blood glucose levels, and improved sleep quality. In addition, participants reported improved quality of life, ease of use, and efficient connectivity to the continuous glucose monitoring system as being valuable features of the system. Conclusions: Continued real-world use of the t:slim X2 pump with Control-IQ technology showed improvements in psychosocial outcomes and persistent achievement of recommended TIR glycemic outcomes in people with T1D.

Keywords: Artificial pancreas; Automated insulin delivery; Glycemic control; Patient-reported outcomes; Type 1 diabetes.

PubMed Disclaimer

Conflict of interest statement

J.E.P. reports grant support, provided to his institution, consulting fees, and speaker fees from Tandem Diabetes Care, Inc; grant support, provided to his institution, and advisory board fees from Medtronic; grant support, provided to his institution, and consulting fees from Eli Lilly; grant support and supplies, provided to his institution, from Insulet; and supplies, provided to his institution, from Dexcom, Inc., L.M. reports grant support from Dexcom, Inc., and consulting from Tandem Diabetes Care, Inc., A.C., S.L., M.M., M.M.M., H.S., and S.H. are employees of Tandem Diabetes Care, Inc.,

Figures

FIG. 1.
FIG. 1.
Study recruitment and analysis.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Brown SA, Kovatchev BP, Raghinaru D, et al. : Six-month randomized, multicenter trial of closed-loop control in type 1 diabetes. N Engl J Med 2019;381:1707–1717 - PMC - PubMed
    1. Dadlani V, Pinsker JE, Dassau E, Kudva YC: Advances in closed-loop insulin delivery systems in patients with type 1 diabetes. Curr Diab Rep 2018;18:88. - PubMed
    1. Pinsker JE, Li Z, Buckingham BA, et al. : Exceptional usability of Tandem t:slim X2 with Basal-IQ predictive low-glucose suspend (PLGS)—The PROLOG Study. Diabetes 2018;67:db18-86-LB.
    1. Barnard K, James J, Kerr D, Adolfsson P, Runion A, Serbedzija G: Impact of chronic sleep disturbance for people living with T1 diabetes. J Diabetes Sci Technol 2016;10:762–767 - PMC - PubMed
    1. Barnard KD, Wysocki T, Ully V, et al. . Closing the loop in adults, children and adolescents with suboptimally controlled type 1 diabetes under free living conditions: a psychosocial substudy. J Diabetes Sci Technol 2017;11:1080–1088 - PMC - PubMed

Publication types